New Netflix Series to Explore the Use of Psychedelics for Mental Health
Over the last decade or so, a growing body of research has revealed a link between mental health and psychedelics. Researchers have found that psychedelic drugs such as LSD and psilocybin have the potential to alleviate mental health conditions, including depression and post-traumatic stress disorder (PTDS). Now a new documentary from Netflix seeks to teach viewers about some of the mental health outcomes associated with psychedelic use.
The documentary is named after Michael Pollan’s book, titled “How to Change Your Mind,” which was originally published in 2018. It will be adapted into film by Academy Award-Winning documentary film director and producer Alex Gibney.
In a prior interview, Pollan stated that although we didn’t know a lot about how psychedelics impact the human mind, they appear to reduce neural activity in a brain network dubbed the “default mode network.” This network is intrinsically involved in our sense of self and reducing its activity or taking it offline is what causes the ego death that is often followed by profound realizations, Poland said.
The new documentary will be spread out over four, 50-minute episodes, each of which will cover either psilocybin, LSD, mescaline or MDMA. The documentary will be directed by two-time Academy Award nominee Lucy Walker and Emmy-nominee Alison Ellwood.
Polland’s book consists of six chapters and an epilogue, with four chapters covering the history and impact of each of the aforementioned substances: chapter 1 covers LSD, chapter 2 talks about psilocybin, chapter 3 explores MDMA (commonly known as ecstasy) and chapter 4 focuses on Mescaline.
The book takes an historical and scientific approach to psychedelics, discussing their history and how people used them in the past as well as the science behind how they work and their impact on mental health. In his interview, Polland stated that at the time, MDMA and psilocybin had exhibited clear medical potential.
Research had found that MDMA could be used to treat trauma and PTSD while psilocybin had proven to be effective at treating anxiety and depression as well as alcohol and nicotine addiction. In recent years, further studies have revealed that psychedelics such as ketamine and mescaline can reduce anxiety, PTSD and depression; they can also have long-lasting mood benefits.
This documentary looks to take a deep dive into the history and science behind these game-changing drugs, with Pollan serving as a guide. “How to Change Your Mind” will be available on Netflix from July 12, 2022.
After watching the series, viewers are likely to have a better understanding of how much companies such as Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) are pushing the frontiers of medicine in order to commercialize approved treatments from different psychedelic compounds.
NOTE TO INVESTORS: The latest news and updates relating to Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) are available in the company’s newsroom at https://ibn.fm/CYBN
Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer
Over the last decade or so, a growing body of research has revealed a link between mental health and psychedelics. Researchers have found that psychedelic drugs such as LSD and psilocybin have the potential to alleviate mental health conditions, including depression and post-traumatic stress disorder (PTDS). Now a new documentary from Netflix seeks to teach viewers about some of the mental health outcomes associated with psychedelic use.
The documentary is named after Michael Pollan’s book, titled “How to Change Your Mind,” which was originally published in 2018. It will be adapted into film by Academy Award-Winning documentary film director and producer Alex Gibney.
In a prior interview, Pollan stated that although we didn’t know a lot about how psychedelics impact the human mind, they appear to reduce neural activity in a brain network dubbed the “default mode network.” This network is intrinsically involved in our sense of self and reducing its activity or taking it offline is what causes the ego death that is often followed by profound realizations, Poland said.
The new documentary will be spread out over four, 50-minute episodes, each of which will cover either psilocybin, LSD, mescaline or MDMA. The documentary will be directed by two-time Academy Award nominee Lucy Walker and Emmy-nominee Alison Ellwood.
Polland’s book consists of six chapters and an epilogue, with four chapters covering the history and impact of each of the aforementioned substances: chapter 1 covers LSD, chapter 2 talks about psilocybin, chapter 3 explores MDMA (commonly known as ecstasy) and chapter 4 focuses on Mescaline.
The book takes an historical and scientific approach to psychedelics, discussing their history and how people used them in the past as well as the science behind how they work and their impact on mental health. In his interview, Polland stated that at the time, MDMA and psilocybin had exhibited clear medical potential.
Research had found that MDMA could be used to treat trauma and PTSD while psilocybin had proven to be effective at treating anxiety and depression as well as alcohol and nicotine addiction. In recent years, further studies have revealed that psychedelics such as ketamine and mescaline can reduce anxiety, PTSD and depression; they can also have long-lasting mood benefits.
This documentary looks to take a deep dive into the history and science behind these game-changing drugs, with Pollan serving as a guide. “How to Change Your Mind” will be available on Netflix from July 12, 2022.
After watching the series, viewers are likely to have a better understanding of how much companies such as Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) are pushing the frontiers of medicine in order to commercialize approved treatments from different psychedelic compounds.
NOTE TO INVESTORS: The latest news and updates relating to Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) are available in the company’s newsroom at https://ibn.fm/CYBN
Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer
